Thursday, January 10, 2013

Is Pfizer Deal the 'Cure-All' for Halozyme Therapeutics

Halozyme (HALO-$7.40) gained more than $147 million in market capitalization on investor excitement that sales from the Pfizer (PFE) collaboration could total $507 million. However, this is an earn-out deal, and most of these millions will only show up on the income statement if – and only if – future development, regulatory and sales-based milestones are reached.

Continue Reading at YCharts: The Story Behind Little Halozyme’s Seemingly Exciting Hookup With Pfizer

Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.

1 comment:

Albuquerque cpa said...

I wanted to thank you for this excellent read!! I definitely loved every little bit of it. I have you bookmarked your site to check out the latest stuff you post.